CD8A and neoplasm: Accordingly, we propose that the enhanced therapeutic efficacy of CAR(NAP) T cells is associated with the ability of secreted NAP to attract and activate innate immune cells to kill tumour cells, and to activate DCs to facilitate the induction of epitope spreading, leading to CAR-target-independent CD8+ T-cell bystander immunity (Fig. 5).